Despite being an unprecedented departure from normal physiology, the combined oral
contraceptive is not only highly effective, but it also has a remarkably good safety record …

Background Little information is available from community-based long-term VTE cohort
studies to compare the absolute thrombosis risk of established clinical and genetic risk …

Background Major concern was raised by an earlier study regarding oral contraceptive use
in women with the factor V Leiden mutation. A more than 30-fold increase in relative risk for …

Abstract Background Direct oral anticoagulants (DOACs) may cause false results of
activated protein C resistance (APC-R) ratio. DOAC-Remove, a new reagent based on …

BACKGROUND: A point mutation in the gene encoding coagulation factor V is a cause of
resistance against activated protein C. The presence of factor V Leiden is linked to 50% of …

OBJECTIVE: To investigate the effects of raloxifene on the hemostatic system in
postmenopausal women. DESIGN: A prospective longitudinal study. SETTING: Outpatient …

Background Community-based cohort studies are not available that evaluated the predictive
power of both clinical and genetic risk factors for venous thromboembolism (VTE). There is …

Uzun yıllar boyunca sadece erişkinleri ilgilendiren bir hastalık grubu olarak bilinen
“trombotik olaylar” son yıllarda pediatrik hematoloji ve genel pediatri pratiğinde sık tartışılan …

The discovery of the resistance to activated protein C (APCR) has provoked a new insight
into the etiopathogenesis of venous and arterial thrombosis. APCR is determined in 95 …

The molecular defect underlying activated protein C resistance (APC-R) is caused by a G to
A point mutation in the codon for arginine 506 in the factor V gene (factor V Leiden) which is …